Search Results - "Rubio Terres, C."

Refine Results
  1. 1

    Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain by Moya-Alarcón, C, Azanza, J R, Barberán, J, Ferrer, R, Kwon, M, Moreno, A, Rubio-Terrés, C, Gálvez-Santisteban, M

    Published in Expert review of anti-infective therapy (02-08-2024)
    “…Invasive fungal infections (IFI) are associated with significant morbidity and mortality. The objective of this work was to compare the costs per adult…”
    Get more information
    Journal Article
  2. 2

    Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study by Rubio-Terrés, C., Garau, J., Grau, S., Martinez-Martinez, L.

    Published in Clinical microbiology and infection (01-06-2010)
    “…The aim of this study was to determine the impact on healthcare resource utilization and associated costs of bacteraemia due to methicillin-resistant…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain by Poveda, J L, Trillo, J L, Rubio-Terrés, C, Rubio-Rodríguez, D, Polanco, A, Torres, C

    “…To estimate the cost-effectiveness of Cladribine Tablets in the treatment of relapsing multiple sclerosis (RMS) with high disease activity compared with…”
    Get more information
    Journal Article
  5. 5

    Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients by Grau, S, Pozo, J C, Romá, E, Salavert, M, Barrueta, J A, Peral, C, Rodriguez, I, Rubio-Rodríguez, D, Rubio-Terrés, C

    Published in ClinicoEconomics and outcomes research (01-01-2015)
    “…To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of…”
    Get full text
    Journal Article
  6. 6

    Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism by Rubio-Terrés, C., Soria, J. M., Morange, P. E., Souto, J. C., Suchon, P., Mateo, J., Saut, N., Rubio-Rodríguez, D., Sala, J., Gracia, A., Pich, S., Salas, E.

    Published in Applied health economics and health policy (01-04-2015)
    “…Background Patients with venous thromboembolism (VTE) commonly have an underlying genetic predisposition. However, genetic tests nowadays in use have very low…”
    Get full text
    Journal Article
  7. 7

    Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment by Ramírez de Arellano, A., Coca, A., de la Figuera, M., Rubio-Terrés, C., Rubio-Rodríguez, D., Gracia, A., Boldeanu, A., Puig-Gilberte, J., Salas, E.

    Published in Applied health economics and health policy (01-10-2013)
    “…Background A clinical–genetic function (Cardio inCode ® ) was generated using genetic variants associated with coronary heart disease (CHD), but not with…”
    Get full text
    Journal Article
  8. 8

    Cost-Effectiveness Analysis of the Treatment of Ventilator-Associated Pneumonia with Linezolid or Vancomycin in Spain by Grau, S., Alvarez-lerma, F., Del castillo, A., Neipp, R., Rubio-terrés, C.

    Published in Journal of chemotherapy (Florence) (01-04-2005)
    “…The aim of this study was to assess the cost-effectiveness of linezolid (LIN) versus vancomycin (VAN) for the treatment of ventilator-associated pneumonia…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain by Rubio-Terrés, C, Domínguez-Gil Hurlé, A

    Published in Revista de neurologiá (16-06-2005)
    “…To carry out a cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis (RRMS) with azathioprine (Imurel) or beta interferon (all,…”
    Get full text
    Journal Article
  11. 11

    Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review by Baca Baldomero, E, Rubio-Terrés, C

    Published in Actas españolas de psiquiatría (01-05-2006)
    “…To compare the efficiency of the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) with venlafaxine in comparison with…”
    Get more information
    Journal Article
  12. 12

    Cost-Effectiveness of Enoxaparin as Thromboprophylaxis in Acutely Ill Medical Patients in Spain by Nuijten, M.J.C., Villar, F. Antoñanzas, Kosa, J., Nadipelli, V., Rubio-Terrés, C., Suarez, C.

    Published in Value in health (01-03-2003)
    “…The objective of this study was to determine the cost-effectiveness of thromboprophylaxis with enoxaparin versus no thromboprophylaxis in patients with acute…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain by Sánchez-Cenizo, Laura, Aller, Javier, Martínez-Sesmero, José Manuel, Mir, Nuria, Peral, Carmen, Rubio-Rodríguez, Darío, Rubio-Terrés, Carlos

    Published in ClinicoEconomics and outcomes research (01-07-2019)
    “…To evaluate the burden of diabetes mellitus (DM) in adult patients with acromegaly treated with second-line pharmacotherapy, from the perspective of the…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20